Go Woon Kim
Overview
Explore the profile of Go Woon Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoo J, Kim G, Jeon Y, Lee S, Kwon S
Cell Death Dis
. 2024 Jun;
15(6):451.
PMID: 38926399
Advances in functional studies on epigenetic regulators have disclosed the vital roles played by diverse histone lysine demethylases (KDMs), ranging from normal development to tumorigenesis. Most of the KDMs are...
2.
Kim J, Cho H, Yoo J, Kim G, Jeon Y, Lee S, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831463
Melanoma is the most lethal type of skin cancer, and it causes more than 55,000 deaths annually. Although regional melanoma can be surgically removed, once melanoma metastasizes to other regions...
3.
Yoo J, Kim G, Jeon Y, Kim J, Lee S, Kwon S
Exp Mol Med
. 2022 Dec;
54(12):2107-2117.
PMID: 36509829
Distinct epigenetic modifiers ensure coordinated control over genes that govern a myriad of cellular processes. Growing evidence shows that dynamic regulation of histone methylation is critical for almost all stages...
4.
Kim J, Cho H, Yoo J, Kim G, Jeon Y, Lee S, et al.
Cells
. 2022 Oct;
11(19).
PMID: 36231123
Histone deacetylase 8 (HDAC8) is a class I HDAC that catalyzes the deacetylation of histone and non-histone proteins. As one of the best-characterized isoforms, numerous studies have identified interacting partners...
5.
Kim J, Han S, Yoo J, Kim G, Jeon Y, Lee S, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955780
HDAC6 is overexpressed in ovarian cancer and is known to be correlated with tumorigenesis. Accordingly, ACY-241, a selective HDAC6 inhibitor, is currently under clinical trial and has been tested in...
6.
Jeon Y, Kim G, Kim S, Yi S, Yoo J, Kim J, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35159030
Dysregulation of epigenetic mechanisms as well as genomic mutations contribute to the initiation and progression of cancer. In addition to histone code writers, including histone lysine methyltransferase (KMT), and histone...
7.
Lee B, Shin M, Hwang I, Jung J, Shim Y, Kim G, et al.
Int J Mol Sci
. 2021 Nov;
22(22).
PMID: 34830173
As major components of spider venoms, neurotoxic peptides exhibit structural diversity, target specificity, and have great pharmaceutical potential. Deep learning may be an alternative to the laborious and time-consuming methods...
8.
Kim G, Chung S
Korean J Physiol Pharmacol
. 2021 Jun;
25(4):333-339.
PMID: 34187950
Injection lipolysis or mesotherapy gained popularity for local fat dissolve as an alternative to surgical liposuction. Phosphatidylcholine (PPC) and aminophylline (AMPL) are commonly used compounds for mesotherapy, but their efficacy...
9.
Yoo J, Jeon Y, Lee D, Kim G, Lee S, Kim S, et al.
Oncol Lett
. 2021 Feb;
21(3):201.
PMID: 33574940
Histone deacetylase 6 (HDAC6)-selective inhibitors are potent anticancer agents that are gaining increasing attention and undergoing various developments. These have been approved or are under clinical trials for use with...
10.
Lee S, Yeon S, Kim G, Lee D, Jeon Y, Yoo J, et al.
Int J Mol Sci
. 2021 Feb;
22(3).
PMID: 33572814
Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance...